GeneTx and Ultragenyx get UK approval for Angelman syndrome trial,

In non-clinical studies, GTX-102 decreased UBE3A-AS levels and reactivated the expression of the paternal UBE3A allele in neurons of the CNS. The …, In non-clinical studies, GTX-102 decreased UBE3A-AS levels and reactivated the expression of the paternal UBE3A allele in neurons of the CNS. The …, Read More

Scroll to Top